I have only been a shareholder since February and

I have only been a shareholder since February and have definitely heard the stories for sure. But I am seeing things align in the company that tell me they have learned from a few missteps. And I can say, small companies Cytodyn’s size will make them regardless of who is in charge. The recent hiring of the CSO and BLA expertise tells me they know they weren’t up to par before the hiring. The advisory board is also a critical step taken to shore up relationships in the medical community and can help generate interest in future trials. So I am seeing progress.